| SARS-CoV-2 PCR Cycle Threshold Trends in Immunocompromised Patients and Implications for Isolation Precautions CE Harris, V Vaidya, Z Lan, M Klompas, C Rhee, L Baden, MA Baker Open Forum Infectious Diseases, ofae367, 2024 | | 2024 |
| Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial SR Walsh, CL Gay, ST Karuna, O Hyrien, T Skalland, KH Mayer, ... PLoS medicine 21 (6), e1004329, 2024 | | 2024 |
| Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020) A Bhimraj, RL Morgan, AH Shumaker, V Lavergne, L Baden, VCC Cheng, ... Clinical Infectious Diseases 78 (7), e83-e102, 2024 | 2 | 2024 |
| Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series AC Sherman, SD van Haren, E Borberg, Z Swank, M Aleissa, A Tong, ... Vaccine, 2024 | | 2024 |
| Immune profiling of age and adjuvant-specific activation of human blood mononuclear cells in vitro SS Schüller, S Barman, R Mendez-Giraldez, D Soni, J Daley, LR Baden, ... Communications Biology 7 (1), 709, 2024 | | 2024 |
| Audio Interview: Preparing for a Possible Avian Influenza Outbreak EJ Rubin, LR Baden, D Daskalakis, H Marston, S Morrissey New England Journal of Medicine 390 (21), e55, 2024 | | 2024 |
| Audio Interview: The Current State of Avian Influenza EJ Rubin, LR Baden, J Marrazzo, A Monto, S Morrissey New England Journal of Medicine 390 (21), e54, 2024 | | 2024 |
| Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans WB Williams, SM Alam, G Ofek, N Erdmann, DC Montefiori, MS Seaman, ... Cell 187 (12), 2919-2934. e20, 2024 | 2 | 2024 |
| How To Measure Benefit in a Changing Pandemic—Olgotrelvir for SARS-CoV-2 AC Sherman, LR Baden NEJM evidence 3 (6), EVIDe2400144, 2024 | | 2024 |
| SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials LH Fisher, JJ Kee, A Liu, CM Espinosa, AK Randhawa, J Ludwig, ... JAMA Network Open 7 (5), e2412835-e2412835, 2024 | | 2024 |
| Coronavirus Disease 2019 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized controlled Trials AC Sherman, J Tuan, VD Cantos, O Adeyiga, S Mahoney, ... Clinical Infectious Diseases, ciae192, 2024 | | 2024 |
| A hiv-1 gp41 peptide-liposome vaccine elicits neutralizing epitope-targeted antibody responses in healthy individuals NB Erdmann, WB Williams, SR Walsh, N Grunenberg, PT Edlefsen, ... medRxiv, 2024 | 1 | 2024 |
| Long-term safety and efficacy of COVE study open-label and booster phases L Baden, H El Sahly, B Essink, D Follmann, G Hachigian, C Strout, ... | | 2024 |
| Neuroinvasive Bacillus cereus Infection in Immunocompromised Hosts: Epidemiologic Investigation of 5 Patients With Acute Myeloid Leukemia JS Little, C Coughlin, C Hsieh, M Lanza, WY Huang, A Kumar, ... Open Forum Infectious Diseases 11 (3), ofae048, 2024 | 1 | 2024 |
| Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB–Containing Vaccines S Chalkias, N McGhee, JL Whatley, B Essink, A Brosz, JE Tomassini, ... The Journal of Infectious Diseases, jiae067, 2024 | 12 | 2024 |
| Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials C Axfors, AM Schmitt, P Janiaud, J van’t Hooft, S Abd-Elsalam, EF Abdo, ... nature communications 15 (1), 1075, 2024 | 8 | 2024 |
| Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial MD Miner, A Decamp, N Grunenberg, SC De Rosa, A Fiore-Gartland, ... Ebiomedicine 100, 2024 | 1 | 2024 |
| Opportunistic infections in patients receiving post-transplantation cyclophosphamide: impact of haploidentical versus unrelated donor allograft JS Little, R Duléry, RM Shapiro, MM Aleissa, SE Prockop, J Koreth, J Ritz, ... Transplantation and Cellular Therapy 30 (2), 233. e1-233. e14, 2024 | 3 | 2024 |
| IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition BS Haslund-Gourley, K Woloszczuk, J Hou, J Connors, G Cusimano, ... Nature communications 15 (1), 404, 2024 | 1 | 2024 |
| Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study A Ozonoff, ND Jayavelu, S Liu, E Melamed, CE Milliren, J Qi, LN Geng, ... Nature communications 15 (1), 216, 2024 | 6 | 2024 |
